Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 14/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20956773 | 1.00 | CHRM3 (0.41) | CHRM3DPP4DPP8CYP2D6DPP9 | |
| SCHEMBL19540688 | 0.84 | APP (0.49) | CHRM3HDAC1ALDH1A1 | |
| SCHEMBL15575406 | 0.83 | HDAC3 (0.42) | DPP4DPP8DPP9DPP7HDAC1 | |
| SCHEMBL20956800 | 0.82 | HCAR3 (0.45) | ALDH1A1 | |
| SCHEMBL15575353 | 0.82 | PTGER4 (0.52) | DPP4ALDH1A1 | |
| SCHEMBL1047697 | 0.81 | PTGER4 (0.36) | DPP4DPP8CYP2D6DPP9DPP7 | |
| SCHEMBL23119908 | 0.80 | HDAC1 (0.40) | HDAC1ALDH1A1 | |
| SCHEMBL20956856 | 0.80 | HDAC1 (0.40) | DPP4DPP8DPP9DPP7HDAC1 | |
| SCHEMBL20956830 | 0.80 | HDAC1 (0.40) | DPP4DPP8DPP9DPP7HDAC1 | |
| SCHEMBL20956857 | 0.80 | HDAC1 (0.40) | DPP4DPP8DPP9DPP7HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135794-A1 | BENZIMIDAZOLE-LINKED INDOLE COMPOUND ACTING AS NOVEL DIVALENT IAP ANTAGONIST | MEDSHINE DISCOVERY INC. (CN) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135794-A1 | BENZIMIDAZOLE-LINKED INDOLE COMPOUND ACTING AS NOVEL DIVALENT IAP ANTAGONIST | BIRC2, BIRC5, BIRC8 | CHRM3 3644/4885DPP4 141/4885DPP8 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.